Topic: Omicron Ba 2

Health officials monitor the rise of the Omicron sub-variant BA.2, which has led to a 10% increase in global COVID-19 cases. While the strain does not appear to cause more severe illness than the original Omicron, positivity rates in several U.S. regions are slowly creeping upward. The segment notes that leaders are following federal guidance and science regarding testing and hospitalization risks.

Infectious disease expert Michael Osterholm warns that the new BA.5 Omicron sub-variant is so transmissible that a single elevator ride could lead to infection. The discussion also references a British Medical Journal (BMJ) analysis suggesting that COVID-19 vaccines may carry a higher risk of hospitalization than previously reported.

China has implemented massive new lockdowns in cities like Shenzhen and Dongguan, affecting over 51 million people, in response to the Omicron BA.2 sub-variant. These "Zero-COVID" measures have raised significant concerns about further disruptions to global supply chains. Some analysts suspect the timing of these lockdowns may be strategically linked to the ongoing conflict in Ukraine or domestic economic goals.

The CDC reported a significant increase in COVID-19 presence at 37% of its monitored wastewater sites between late February and early March. While cases across the U.S. are currently down, officials warn that wastewater data can be a leading indicator of a spring surge driven by the BA.2 variant. However, some experts argue that wastewater is actually a lagging indicator and that high detection levels without corresponding hospitalizations suggest the pandemic phase is ending.

Pfizer has submitted data to the FDA requesting emergency use authorization for a fourth dose of its COVID-19 vaccine for individuals aged 65 and older. The request is based on two sets of data from Israel suggesting that an additional booster improves protection against severe illness from the Omicron variant. This move comes as the BA.2 sub-variant begins to make up a larger percentage of new cases in the United States.

Health officials are tracking a sub-variant of Omicron known as BA.2, or "Stealth Omicron," which has been detected in over 50 countries. Pfizer has initiated trials for an Omicron-specific booster, while some analysts suggest the focus on new variants is a strategy to move existing vaccine inventory. Experts in Scandinavia describe BA.2 as more transmissible but likely similar in clinical severity to the original Omicron strain.